Watch AUPH. Know when insiders buy.
One email the day a filing lands. Free.
Work order
42
WATCH · insiders 35, shorts 48
Insiders, 90 days
−$356K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.1BP/E 7.0DIV YIELD —FCF YIELD —REV TTM $311.5M +19.8%NET INCOME $314.1M +418.0%NET CASH —52W 11.05 – 18.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $83.2M | +18.9% | 92.1% | $46.3M | $37.4M | +73.9% | 0.28 | $52.6M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $77.7M | +24.4% | 91.6% | $41.4M | $34.4M | +47.2% | 0.25 | $32.6M | — | — | Aug 6 |
| Q4 2025 · Dec 31 | $77.1M | +28.8% | 88.6% | $33.2M | $210.8M | +14651.2% | 1.53 | $45.7M | — | — | Feb 26 |
| Q3 2025 · Sep 30 | $73.5M | +8.4% | 88.9% | $29.7M | $31.6M | +119.9% | 0.23 | $44.4M | — | — | Feb 26 |
| Q2 2025 · Jun 30 | $70M | +22.4% | 89.8% | $20.1M | $21.5M | +2879.6% | 0.16 | $44.2M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $62.5M | +24.2% | 86.3% | $21.8M | $23.3M | — | 0.16 | $1.3M | — | — | Aug 6 |
| Q4 2024 · Dec 31 | $59.9M | +32.8% | 90.7% | −$1.7M | $1.4M | — | 0.01 | $30.1M | — | — | Feb 26 |
| Q3 2024 · Sep 30 | $67.8M | +24.3% | 91.1% | $11.7M | $14.3M | — | 0.10 | $17M | — | — | Feb 26 |
| Q2 2024 · Jun 30 | $57.2M | — | 84.4% | −$1.5M | $722K | — | 0.01 | $15.8M | — | — | Feb 26 |
| Q1 2024 · Mar 31 | $50.3M | — | 84.6% | −$13.3M | −$10.7M | — | -0.07 | −$18.6M | — | — | Feb 26 |
| Q4 2023 · Dec 31 | $45.1M | — | 88.0% | −$29.7M | −$26.9M | — | -0.19 | $14.3M | — | — | Feb 26 |
| Q3 2023 · Sep 30 | $54.5M | — | 87.6% | −$16.3M | −$13.4M | — | -0.09 | −$13.3M | — | — | Feb 27 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $283.1M | 88.5% | $104.9M | $287.2M | 101.5% | 2.07 | $135.7M | — | — | $98.2M | — |
| FY2024 · to Dec 31 | $235.1M | 88.0% | −$4.7M | $5.8M | 2.4% | 0.04 | $44.4M | — | — | $40.2M | — |
| FY2023 · to Dec 31 | $175.5M | 91.9% | −$91.7M | −$78M | -44.5% | -0.54 | −$33.5M | — | — | $0 | — |
| FY2022 · to Dec 31 | $134M | 95.8% | −$111.5M | −$108.2M | -80.7% | -0.76 | −$79.5M | — | — | $0 | — |
| FY2021 · to Dec 31 | $45.6M | 97.6% | −$180.7M | −$181M | -396.8% | -1.40 | −$157.7M | — | — | — | — |
| FY2020 · to Dec 31 | $50.1M | 100.0% | −$104.3M | −$102.7M | -204.9% | -0.87 | −$69.9M | — | — | — | — |
Every number comes from Aurinia Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.